📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
48 announcements match the current filters (relevance ≥ 5).
Apollo Hospitals Q3FY26 Standalone PAT up 12% YoY to ₹384 Cr; Declares ₹10 Interim Dividend
Apollo Hospitals reported a robust performance for Q3FY26 with standalone revenue growing 15% YoY to ₹2,364 crore. Standalone EBITDA increased by 16% YoY to ₹594 crore, while Profit After Tax rose 12% to ₹384 crore, despite a one-time exceptional charge of ₹11.4 crore related to new labour codes. The Board has declared an interim dividend of ₹10 per share (200% of face value) with a record date of February 16, 2026. The company is also progressing with its strategic restructuring to demerge its pharmacy and digital health businesses.
Key Highlights
Standalone Revenue from operations grew 15% YoY to ₹23,637 million compared to ₹20,548 million in Q3FY25.
Standalone EBITDA rose 16% YoY to ₹5,935 million from ₹5,118 million in the previous year.
Interim dividend of ₹10 per share declared; Record date fixed as February 16, 2026.
Profit After Tax (PAT) increased 12.3% YoY to ₹3,835 million despite an exceptional cost of ₹114 million.
Company has filed an application with NCLT for the demerger of its pharmacy distribution and digital health platform.
👀 What to Watch
Investors should take note of the steady double-digit growth across key financial metrics and the healthy dividend payout. The upcoming demerger of the pharmacy and digital health business remains a key monitorable for long-term value unlocking.
Apollo Hospitals Declares ₹10 Interim Dividend; Q3 PAT Rises 12% YoY to ₹3,835 Million
Apollo Hospitals has declared an interim dividend of ₹10 per share (200% of face value) for FY26, with the record date fixed for February 16, 2026. The company reported a 15% YoY growth in standalone revenue to ₹23,637 million for the quarter ended December 31, 2025. Standalone Profit After Tax (PAT) grew by 12% YoY to ₹3,835 million, even after accounting for a ₹114 million exceptional charge related to new labour codes. Additionally, the company is progressing with its composite scheme of arrangement for the demerger of its pharmacy and digital health businesses, currently awaiting NCLT approval.
Key Highlights
Interim dividend of ₹10 per share (200% of FV) declared with a record date of February 16, 2026.
Standalone Revenue from operations increased 15% YoY to ₹23,637 million in Q3 FY26.
EBITDA grew 16% YoY to ₹5,935 million, maintaining healthy operational margins.
Net Profit (PAT) for the quarter stood at ₹3,835 million compared to ₹3,416 million in the previous year.
Exceptional item of ₹114 million recorded due to regulatory changes in Labour Codes affecting employee benefits.
👀 What to Watch
Investors seeking dividend income should ensure they hold the stock before the February 16 record date. Long-term investors should track the NCLT approval process for the pharmacy business demerger as it could unlock significant value.
Apollo Hospitals Q3 PAT Rises 12% to ₹383.5 Cr; Declares ₹10 Interim Dividend
Apollo Hospitals Enterprise Limited reported a steady performance for Q3 FY26, with standalone revenue from operations growing 15% YoY to ₹2,363.7 crore. Net profit increased by 12.3% YoY to ₹383.5 crore, despite a one-time exceptional charge of ₹11.4 crore due to new labour code provisions. The company rewarded shareholders with an interim dividend of ₹10 per share. Furthermore, the company has moved forward with its restructuring plan, filing an application with the NCLT for the demerger of its pharmacy and digital health businesses.
Key Highlights
Standalone Revenue from operations increased 15% YoY to ₹2,363.7 crore from ₹2,054.8 crore.
EBITDA grew by 16% YoY to ₹593.5 crore compared to ₹511.8 crore in the same quarter last year.
Profit After Tax (PAT) stood at ₹383.5 crore, up from ₹341.6 crore in Q3 FY25.
Declared an interim dividend of ₹10 per share (200% of face value) with a record date of Feb 16, 2026.
Exceptional item of ₹11.4 crore recognized due to increased gratuity and leave liabilities under new Labour Codes.
👀 What to Watch
Investors should maintain a positive outlook given the consistent growth in the core healthcare segment and the upcoming value unlocking from the pharmacy business demerger. The interim dividend provides an immediate yield benefit while waiting for the restructuring to conclude.
CRISIL Revises Apollo Hospitals' Outlook to 'Positive'; Reaffirms 'AA+' Rating
CRISIL Ratings has revised the outlook on Apollo Hospitals Enterprise Ltd (AHEL) to 'Positive' from 'Stable' while reaffirming its 'CRISIL AA+' rating. This revision reflects AHEL's dominant market position as India's largest private healthcare provider and expectations of sustained mid-teen revenue growth. The company is projected to achieve consolidated revenues of over Rs. 24,000 crores in fiscal 2026 with healthy EBITDA margins of 23-24% post-demerger of its pharmacy business. Despite a planned capex of Rs. 6,000 crore for bed expansion, the company maintains a robust financial profile with a cash surplus of Rs. 3,222 crore.
Key Highlights
Long-term rating outlook revised to 'Positive' from 'Stable'; 'CRISIL AA+' rating reaffirmed.
Consolidated revenue estimated to grow 12-15% YoY to over Rs. 24,000 crores in fiscal 2026.
Planned capex of ~Rs. 6,000 crore to add 3,600+ beds over the next 3-5 years.
Strong liquidity position with cash and cash equivalents of Rs. 3,222 crore as of September 30, 2025.
Debt/EBITDA estimated at 1.65x for FY26, with expectations to drop below 1.5x by FY27.
👀 What to Watch
The outlook revision to 'Positive' indicates a potential rating upgrade in the medium term, reflecting strong operational cash flows and market leadership. Investors should view this as a sign of high credit quality and financial stability as the company executes its massive bed expansion plan.
Apollo Hospitals gets CCI nod to acquire 30.58% stake in AHLL for Rs 12,540.68 million
Apollo Hospitals Enterprise Limited has received approval from the Competition Commission of India (CCI) to acquire a 30.58% equity stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The acquisition involves purchasing 41,650,368 equity shares from the International Finance Corporation (IFC) and IFC EAF for a total consideration of Rs 12,540.68 million. This move consolidates Apollo's ownership in its retail healthcare arm, which includes clinics, diagnostics, and primary care. The transaction follows the initial board approval granted in September 2025.
Key Highlights
CCI approved the acquisition of 41,650,368 equity shares (30.58% stake) in AHLL.
The total purchase consideration for the stake is Rs 12,540.68 million.
The stake is being acquired from International Finance Corporation (IFC) and IFC EAF Apollo Investment Company.
This acquisition increases Apollo's control over its high-growth retail healthcare and diagnostics business.
👀 What to Watch
Investors should view this consolidation of a key subsidiary as a positive long-term move for earnings accretion. Monitor the impact on the company's cash flow and the subsequent growth trajectory of the AHLL segment.
Apollo Hospitals gets CCI nod to acquire 30.58% stake in AHLL for ₹1,254 crore
Apollo Hospitals Enterprise Limited has received approval from the Competition Commission of India (CCI) to acquire a 30.58% equity stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The company will purchase 41,650,368 equity shares from the International Finance Corporation (IFC) and IFC EAF for a total consideration of Rs 12,540.68 million. This acquisition, originally approved by the board in September 2025, consolidates Apollo's ownership in its retail healthcare and diagnostics arm. The regulatory clearance marks a significant milestone in completing this strategic transaction.
Key Highlights
CCI approved the acquisition of 41,650,368 equity shares in subsidiary AHLL.
The 30.58% stake is being acquired for a total purchase consideration of Rs 12,540.68 million.
The stake was jointly held by International Finance Corporation (IFC) and IFC EAF Apollo Investment Company.
The acquisition follows the board's prior approval granted on September 12, 2025.
Consolidates ownership in the high-growth retail healthcare and lifestyle business segment.
👀 What to Watch
Investors should view this consolidation of ownership in a key subsidiary as a positive move for long-term value creation. Monitor the impact on consolidated earnings as the company gains full control over AHLL's cash flows.
Apollo Hospitals Gets NSE 'No Objection' for Apollo Healthtech Demerger and Merger Scheme
Apollo Hospitals Enterprise Limited (AHEL) has received a 'No Objection' letter from the National Stock Exchange (NSE) for its proposed composite scheme of arrangement. The scheme involves the demerger of an identified business undertaking into Apollo Healthtech Limited, alongside the amalgamation of Apollo Healthco and Keimed Private Limited into the same entity. This follows the prior approval from the Competition Commission of India (CCI) received in September 2025. The company is now authorized to file the scheme with the National Company Law Tribunal (NCLT) for final approval.
Key Highlights
NSE issued the 'No Objection' letter on December 23, 2025, which is valid for six months for NCLT filing.
The restructuring involves the demerger of an identified business and the merger of Apollo Healthco and Keimed Private Limited.
Apollo Healthtech Limited (the Resultant Company) is slated for listing on both NSE and BSE post-restructuring.
The company must ensure that trading in new securities commences within 60 days of the final NCLT order.
CCI approval for the transactions was previously secured on September 24, 2025.
👀 What to Watch
Investors should view this as a significant step toward value unlocking in the pharmacy and digital health segments. Monitor the NCLT approval timeline and the specific share entitlement ratios for the new entity.
Apollo Hospitals Receives NSE 'No Objection' for Composite Scheme of Arrangement
Apollo Hospitals (AHEL) has received a 'no objection' letter from the National Stock Exchange (NSE) for its proposed composite scheme of arrangement. The scheme involves the demerger of an identified business undertaking into Apollo Healthtech Limited and the amalgamation of Apollo Healthco and Keimed Private Limited into the same entity. This regulatory milestone follows the prior approval from the Competition Commission of India (CCI) received in September 2025. The restructuring aims to consolidate the health-tech and pharmacy distribution businesses, leading to a separate listing of Apollo Healthtech.
Key Highlights
Received NSE 'No Objection' letter on December 23, 2025, for the composite scheme of arrangement.
Scheme involves demerger of identified business and merger of Apollo Healthco and Keimed into Apollo Healthtech Limited.
The Resultant Company, Apollo Healthtech, is proposed to be listed on both NSE and BSE post-scheme completion.
The validity of the NSE observation letter is six months, within which the scheme must be submitted to the NCLT.
The transaction remains subject to approvals from NCLT, shareholders, and creditors of the involved entities.
👀 What to Watch
Investors should monitor the upcoming NCLT proceedings and shareholder meetings as this restructuring is a key step toward value unlocking in the health-tech segment. The eventual listing of Apollo Healthtech could provide a distinct valuation for the digital and distribution business.
